Research progress in the role of microRNA-155 in regulation of autophagy and diagnosis and treatment for gastric cancer.
10.11817/j.issn.1672-7347.2019.01.014
- Author:
Gang CHEN
1
;
Minmin ZHANG
2
;
Yumin LI
1
Author Information
1. Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou 730030; First Department of General Surgery, Second Hospital, Lanzhou University, Lanzhou 730030, China.
2. School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, China.
- Publication Type:Journal Article
- MeSH:
Autophagy;
Cell Line, Tumor;
China;
Gene Expression Regulation, Neoplastic;
Humans;
MicroRNAs;
genetics;
Stomach Neoplasms;
genetics
- From:
Journal of Central South University(Medical Sciences)
2019;44(1):87-91
- CountryChina
- Language:Chinese
-
Abstract:
China is one of the regions with a high incidence of gastric cancer worldwide. Low detection rate and poor curative effect lead to unsatisfied prognosis and low five-year survival rate. Surgery combined with radiotherapy and chemotherapy is the mainstream comprehensive treatment scheme, however, multi-drug resistance may gradually prevail in the chemotherapy process. Chemotherapy, miRNA and autophagy interact with each other, but the mechanism is complex. MiR-155 is abnormally expressed in gastric cancer, which could promote autophagy, inhibit apoptosis, and interact with Helicobacter pylori to induce gastric cancer. Through its regulatory effect on autophagy, miR-155 can be used to treat gastric cancer, improve chemotherapy sensitivity and reverse drug resistance. The high expression of miR-155 in gastric cancer tissues suggests poor prognosis.
